Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent De...(ptember 30 ...),Health

Date:11/9/2009

ptember 30, ------------------ ----------------- 2009 2008 2009 2008 ---- ---- ---- ---- (unaudited) (unaudited) Revenues Manufacturing services $1,737 $1,442 $4,663 $5,461 Collaborative agreements 882 415 3,042 1,650 --- --- ----- ----- Total revenues 2,619 1,857 7,705 7,111 Operating Expenses Cost of manufacturing services 1,705 1,743 4,702 6,362 Research and development 22,147 47,475 88,972 151,050 General and administrative 5,423 5,924 18,725 21,938 Restructuring charges - - 3,324 - Amortization of acquired technology & other intangibles 582 580 1,721 1,748 --- --- ----- ----- Total operating expenses 29,857 55,722 117,444 181,098 Interest and Other Income (Expense) Interest income 75 1,332 291 6,529 Interest expense (7,339) (1,399) (10,991) (4,367) Gain from valuation of derivative liabilities 2,472 - 345 - Warrant settlement expense - (242) - (2,236) Loss on extinguishment of debt (2,479) - (2,479) - Other (326) (1,453) (859) (1,299) ---- ------ ---- ------ Total interest and other expense, net (7,597) (1,762) (13,693) (1,373) ------
'/>"/>

SOURCE Arena Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals